Free tool
FAERS Monitor: Ixempra Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022065 or its brand name (Ixempra Kit, Ixabepilone). Reports on generic versions are filed under their own applications.
Reports
1,051
Serious
857
82% of reports
Hospitalization
421
Death reported
242
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death106
- vomiting94
- nausea93
- anaemia91
- fatigue89
- diarrhoea76
- malignant neoplasm progression70
- neutropenia70
- white blood cell count decreased69
- neutrophil count decreased67
- dyspnoea60
- dehydration57
- neuropathy peripheral52
- febrile neutropenia49
- disease progression45
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 21 |
| 2006 | 27 |
| 2007 | 23 |
| 2008 | 95 |
| 2009 | 79 |
| 2010 | 85 |
| 2011 | 57 |
| 2012 | 139 |
| 2013 | 84 |
| 2014 | 81 |
| 2015 | 70 |
| 2016 | 117 |
| 2017 | 52 |
| 2018 | 30 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 15 |
| 2022 | 23 |
| 2023 | 4 |
| 2024 | 9 |
| 2025 | 9 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,108 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neutrophil count decreasedSignal | 67 | 32.9 | 26.1 | 2,044 |
| febrile neutropeniaSignal | 49 | 14.8 | 11.3 | 618 |
| malignant neoplasm progressionSignal | 70 | 13.7 | 10.9 | 814 |
| white blood cell count decreasedSignal | 69 | 12.7 | 10.1 | 739 |
| neuropathy peripheralSignal | 52 | 10.9 | 8.4 | 462 |
| neutropeniaSignal | 70 | 10.3 | 8.2 | 583 |
| anaemiaSignal | 91 | 9.6 | 7.8 | 694 |
| dehydrationSignal | 57 | 8.6 | 6.6 | 375 |
| disease progressionSignal | 45 | 7.6 | 5.7 | 253 |
| vomitingSignal | 94 | 4.0 | 3.3 | 213 |
| deathSignal | 106 | 2.5 | 2.1 | 94 |
| diarrhoeaSignal | 76 | 2.4 | 1.9 | 60 |
| nauseaSignal | 93 | 2.4 | 1.9 | 74 |
| fatigueSignal | 89 | 2.3 | 1.9 | 66 |
| dyspnoeaSignal | 60 | 2.1 | 1.7 | 35 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.